Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) announced its quarterly earnings results on Tuesday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24), Zacks reports. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. During the same quarter last year, the company earned $1.25 EPS.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.97 on Wednesday. The stock has a market capitalization of $216.87 million, a P/E ratio of 5.59 and a beta of 0.99. The company’s fifty day moving average price is $4.98 and its 200 day moving average price is $5.89. Voyager Therapeutics has a 1 year low of $3.75 and a 1 year high of $10.66.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 over the last 90 days. 4.53% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target on the stock. Wedbush reiterated an “outperform” rating and set a $9.00 price objective (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.72.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.